ClinicalTrials.gg
RecruitingNCT05987644DURABLEUpdated Apr 8, 2026

Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements

A Phase 1/2 interventional study of Alectinib and Stereotactic Radiosurgery in Lung Cancer, NSCLC and Brain Metastases, sponsored by Joshua Palmer. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by Joshua Palmer · Phase 1/2, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,462 studies in Lung Neoplasms with a site in United States — 423 open to participants now, 644 under way, 52 of them phase 3. Lung Neoplasms · United States.

Planned enrollment
840th of 1,908
56 · median 48
Started
2024
with 105 others
Phase 1/2
212 of 2,462
42 open now
Primary completion
2028-02
later than 426 of 638 live
Registered
2,100th of 2,462
by date

Among the 2,462 studies in Lung Neoplasms with a site in United States, this one is the 840th largest by planned enrollment of the 1,908 interventional ones that give a count, is one of 106 that started in 2024, is one of 212 in phase 1/2, reaches primary completion later than 426 of the 638 other live ones, and was the 2,100th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

423 of the 2,462 studies in Lung Neoplasms with a site in United States are open now. Recruiting first, the newest first:

418 more — sign in →

All 423 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,462 studies in Lung Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This study will consist of a Phase 1b and Phase 2 portion. The Phase 1b portion will enroll first followed by the Phase 2 portion. Each cycle of treatment = 28 days.

Subjects will receive alectinib twice daily. Those in the Phase 1b portion will receive alectinib alone. Those in Phase 2 Arm A will receive alectinib alone. Those in Phase 2, Arm B will receive SRS + alectinib.

A maximum of 25 cycles (2 years) of alectinib may be administered on study.

03

Conditions studied

  • Lung Cancer
  • NSCLC
  • Brain Metastases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

General Inclusion Criteria:

Subject must meet all of the following applicable inclusion criteria to participate in this study:

  1. Written and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.
  2. Age ≥ 18 years at the time of consent.
  3. Fluent English skills with comprehensive/speaking skills equal to those of a native English speaker as assessed by the site investigator.
  4. Performance Status of ≤ 2 within 14 days prior to registration.
  5. Histological or cytological confirmation of Stage IV (per AJCC 8th edition) non-small cell lung cancer (NSCLC).
  6. At least one intracranial on MRI imaging.
  7. Confirmation of positive ALK rearrangement per local standard of care testing.
  8. All subjects must have and be either asymptomatic or minimally symptomatic per investigator discretion without plan for surgical intervention within 28 days of study start. Patients with neurological symptoms that are controlled with dose of or anti-epileptic medications are eligible. Patients with asymptomatic may be eligible for trial providing they meet all other eligibility criteria.
  9. Subjects must be planning on therapy with alectinib. Alectinib may have been started up to 8 weeks prior to registration.
  10. Prior non-ALK directed therapy for metastatic disease is permitted. Patients who have received prior or adjuvant chemotherapy, radiotherapy, immunotherapy ( or PD-L1 monoclonal antibodies) or chemoradiotherapy with curative intent for non-metastatic disease must have experienced a treatment-free interval of at least 3 months from registration since the last chemotherapy, radiotherapy, immunotherapy, or chemoradiotherapy cycle.
  11. Documentation of consultation with a radiation oncologist confirming review and approval of the radiation therapy plan as outlined in Section 5.
  12. Demonstrate adequate organ function as defined in the protocol. All screening labs to be obtained within 14 days prior to registration.
  13. Females of must have a negative serum pregnancy test within 14 days prior to registration. See protocol for definition of childbearing potential.
  14. Females of childbearing potential and males must be willing to abstain from heterosexual intercourse or to use an effective method(s) of as outlined in the protocol.
  15. -infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial.
  16. Patients with evidence of chronic virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, the HCV viral load must be undetectable to be eligible for this trial.
  17. As determined by the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study.

Exclusion Criteria:

Subjects meeting any of the criteria below may not participate in the study:

  1. Active infection requiring systemic therapy.
  2. Malabsorption syndrome or other condition that would interfere with enteral absorption
  3. Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).
  4. Patients with a prior or concurrent whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the regimen, per treating physician discretion, are not eligible for this trial.
  5. Treatment with any investigational drug within 28 days prior to registration.
  6. Acute viral, , alcoholic, or other types of acute hepatitis.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    Phase 1b: Experimental

    600mg alectinib taken orally twice daily

    Drug: Alectinib

  • Experimental
    Phase 2: Arm A

    600mg alectinib taken orally twice daily

    Drug: Alectinib

  • Experimental
    Phase 2: Arm B

    Subjects will receive SRS prior to taking alectinib. 24 hours after, but no more than 7 days after last radiation dose, alectinib should be taken at 600mg orally twice daily

    Drug: Alectinib · Radiation: Stereotactic Radiosurgery

Interventions

  • 600mg taken orally, twice daily for 25 Cycles Cycle = 4 weeks (28 days)

  • RadiationStereotactic Radiosurgery

    SRS dose varies by brain met size and location

    Also known as: SRS

06

What researchers measure

Primary outcomes

  1. Phase 2: Neurological status and control of CNS disease at 12 months compared to alectinib plus SRS in patients with ≤15 CNS metastases

    Neurological status will be measured by a composite endpoint of: -Inntracranial progression(icPD) by RANO-BM criteria or death during the first 12 months. OR -Symptomatic radiation necrosis during the first 12 months. Symptomatic radiation necrosis is defined as requiring initiation of or increased dose of steroids or resulting in seizures or requirement of AEDs or requirement of hospitalization or surgery. OR -Cognitive decline, defined as 1 standard deviation decline from baseline cognitive function during the first 12 months.

    Time frame: 12 months

  2. Phase 1b: Safety and Feasibility

    Safety and feasibility will be assessed by frequency of Dose Limiting Toxicities.

    Time frame: 6 months

Secondary outcomes

  1. Intracranial progression-free survival at 12 months (icPFS12)

    icPFS12 is the percentage of patients with icPD at 12 months defined by RANO-BM from randomization or death.

    Time frame: 12 months

  2. Intracranial disease control rate (icDCR)

    icDCR defined as the percentage of patients with a complete response (CR), partial response (PR), or stable disease (SD), per RANO-BM.

    Time frame: 31 months

  3. Intracranial response rate (icRR)

    icRR defined as the percentage of patients with a complete response (CR) and partial response (PR), per RANO-BM.

    Time frame: 31 months

  4. Intracranial duration of response (icDOR)

    icDOR defined as the time when the criteria for CR or PR per RANO-BM were first met to the occurrence of an icPFS event

    Time frame: 31 months

  5. Extracranial PFS

    Extracranial PFS will be defined as time from randomization to progression per RECIST v1.1

    Time frame: 31 months

  6. Assess Overall survival (OS)

    OS defined as the time from randomization to death from any cause.

    Time frame: 31 months

  7. Safety and Tolerability

    Safety and tolerability will be assessed by measuring the frequency and severity of adverse events based on CTCAE v5.0

    Time frame: 6 months

  8. Cognitive decline at 12 and 24 months

    Rate of cognitive decline, defined as 1 standard deviation decline from baseline cognitive function in at least 1 cognitive test.

    Time frame: 12, 24 months

  9. Symptomatic radiation necrosis at 12 and 24 months

    Incidence of symptomatic radiation necrosis, defined as requiring initiation of or increased dose of steroids or resulting in seizures or requirement of AEDs or requirement of hospitalization or surgery.

    Time frame: 12, 24 months

07

Study locations

3 of 3 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Feb 2028, 47 months after the start.

Of 78 non-industry phase 1/2 interventional studies under Lung Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 159. This study's planned 47 months is below that.

Counting every sponsor, half of 157 studies reached it within 54 months; a quarter within 39 and three quarters within 93.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2023
First posted
Aug 14, 2023
StartActual
Mar 7, 2024
Primary completionEst.
Feb 28, 2028
CompletionEst.
Feb 28, 2029
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05987644
Lead sponsor
Joshua Palmer
Collaborators
Genentech, Inc.
Responsible party
Joshua Palmer (Sponsor-Investigator, Hoosier Cancer Research Network) — Sponsor-investigator
First posted
Aug 14, 2023
Start date
Mar 7, 2024
Primary completion
Feb 28, 2028 (estimated)
Completion
Feb 28, 2029 (estimated)
Last update
Apr 8, 2026

Study contacts

Joshua D Palmer, MD
Contact
joshua.palmer@osumc.edu
614-293-0871
Amber Ryba
Contact
aryba@hoosiercancer.org
317-634-5842 ext. 13
Joshua D Palmer, MD
principal investigator · The Ohio State University Comprehensive Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion